MRI Screening for Prostate Cancer
Trial Summary
What is the purpose of this trial?
Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive prostate cancer compared to men in the general population. Standard of care screening for men with a BRCA mutation includes PSA testing and digital rectal examination (DRE), the same as with men in the general population. This study is being done to assess whether there is value in using MRI as a screening tool to detect prostate cancer at an earlier stage than may otherwise be detected using standard of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in this specific population at high risk for aggressive disease.
Research Team
Danny J Vesprini, MD, MSc, FRCPC
Principal Investigator
Sunnybrook Health Sciences Centre
Eligibility Criteria
This trial is for men over 50 who are part of the Male Hereditary Cancer Research Program, have a BRCA1 or BRCA2 mutation, and can undergo an ultrasound biopsy. It's not for those with claustrophobia, MRI contraindications, contrast agent issues, or previous prostate cancer diagnosis.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- MS3TMRI
- TRUS Guided Biopsy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Toronto Sunnybrook Regional Cancer Centre
Lead Sponsor
Women's College Hospital
Collaborator
Sunnybrook Health Sciences Centre
Collaborator